A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition

Cancer Gene Therapy

Volumn 12, Issue 12, 2005, Pages 935-946

  Strauss, Bryan E ^a   Bajgelman, Marcio C ^a   Costanzi Strauss, Eugenia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Doxorubicin; LTR; p53; pCLPG; Retrovirus; Temperature sensitive mutant of p53; Transcriptional regulation

Indexed keywords

COMPLEMENTARY DNA; DOXORUBICIN; PROTEIN P53;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS; TRANSGENICS; TUMOR CELL; WILD TYPE;

CELL LINE; CELL PROLIFERATION; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; PLASMIDS; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; TEMPERATURE; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27744575130     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700846     Document Type: Article

References (49)

1. Valerio D, Einerhand MP, Wamsley PM, et al. Retrovirus-mediated gene transfer into embryonal carcinoma and hemopoietic stem cells: expression from a hybrid long terminal repeat. Gene. 1989;84:419-427.
2. Davis B, Linney E, Fan H. Suppression of leukaemia virus pathogenicity by polyoma virus enhancers. Nature. 1985;314:550-553.
3. Lorens JB, Jang Y, Rossi AB, et al. Optimization of regulated LTR-mediated expression. Virology. 2000;272:7-15.
4. Kim SH, Yu SS, Park JS, et al. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol. 1998;72:994-1004.
5. Indraccolo S, Minuzzo S, Habeler W, et al. Modulation of Moloney leukemia virus long terminal repeat transcriptional activity by the murine CD4 silencer in retroviral vectors. Virology. 2000;276):83-92.
6. Mavria G, Jager U, Porter CD. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Therapy. 2000;7:368-376.
7. Choi JK, Hoang N, Vilardi AM, et al. Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells. Stem Cells. 2001;19:236-246.
8. Lotti F, Menguzzato E, Rossi C, et al. Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol. 2002;76:3996-4007.
9. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
10. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
11. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
12. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
13. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799-1805.
14. Barak Y, Juven T, Haffner R, et al. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993;12:461-468.
15. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 1996;15:1596-1606.
16. Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-299.
17. Funk WD, Pak DT, Karas RH, et al. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol. 1992;12:2866-2871.
18. Miyashita T, Harigai M, Hanada M, et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
19. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;255:459-462.
20. Strauss BE, Shivakumar C, Deb SP, et al. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochemical & Biophysical Research Communications. 1995;217:825-831.
21. Subler MA, Martin DW, Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J Virol. 1992;66:4757-4762.
22. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847-849.
23. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
24. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991;252:1708-1711.
25. Kern SE, Pietenpol JA, Thiagalingam S, et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992;256:827-830.
26. Naviaux RK, Costanzi E, Haas M, et al. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol. 1996;70:5701-5705.
27. Johnson M, Dimitrov D, Vojta PJ, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/ WAF1/p21 RNA in human cells. Mol Carcinog. 1994;11:59-64.
28. Michieli P, Chedid M, Lin D, et al. Induction of WAF1/ CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391-3395.
29. Strauss BE, Costanzi-Strauss E. pCLPG: a p53-driven retroviral system. Virology. 2004;321:165-172.
30. Zhang W, Guo XY, Hu GY, et al. A temperature-sensitive mutant of human p53. EMBO J. 1994;13:2535-2544.
31. Costanzi-Strauss E, Strauss BE, Naviaux RK, et al. Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines. Exp Cell Res. 1998;238:51-62.
32. DuBridge RB, Tang P, Hsia HC, et al. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol. 1987;7:379-387.
33. Strauss B, Fontes R, Lotfi C, et al. Retroviral transfer of the p16INK4a cDNA inhibits C6 glioma formation in Wistar rats. Cancer Cell Int. 2002;2:2.
34. Bajgelman MC, Costanzi-Strauss E, Strauss BE. Exploration of critical parameters for transient retrovirus production. J Biotechnol. 2003;103:97-106.
35. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 1990;62:671-680.
36. Check E. Gene therapy put on hold as third child develops cancer. Nature. 2005;433:561.
37. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev. 2000;10:94-99.
38. Huang Y, Tyler T, Saadatmandi N, et al. Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability. [erratum appears in Cancer Res. 2003 63(16):5171]. Cancer Res. 2003;63:3646-3653.
39. Strauss BE, Haas M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem Biophys Res Commun. 1995;217:333-340.
40. Ugai H, Suzuki E, Inabe K, et al. Spontaneous mutations in the human gene for p53 in recombinant adenovirus during multiple passages in human embryonic kidney 293 cells. Biochem Biophys Res Commun. 2003;300:448-456.
41. Kaiser J. Gene therapy. RAC's advice: proceed with caution. Science. 2002;298:2113-2115.
42. Li Z, Dullmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science. 2002;296:497.
43. Marshall E. Gene therapy. What to do when clear success comes with an unclear risk? Science. 2002;298:510-511.
44. Marshall E. Clinical research. Gene therapy a suspect in leukemia-like disease. Science. 2002;298:34-35.
45. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res. 1993;60:157-180.
46. Hesdorffer C, Ayello J, Ward M, et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 1998;16:165-172.
47. Hanania EG, Giles RE, Kavanagh J, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA. 1996;93:15346-15351.
48. Abonour R, Williams DA, Einhorn L, et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells [see comment]. Nat Med. 2000;6:652-658.
49. Knipper R, Kuehlcke K, Schiedlmeier B, et al. Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Ther. 2001;8:239-246.